Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Diabetic Macular Edema
NCT03622593Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of faricimab in diabetic macular edema (DME) (3 arms), sponsored by Roche. Primary endpoint: Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at 56 weeks. Started Oct 2018; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03622593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622593.